Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673020 · ClinicalTrials.gov registry record · Phase 1
Phase 1a Study to Evaluate Immunogenicity of ASV®
A Phase 1 study, sponsored by Agenus.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03673020: Completed Phase 1 study, sponsored by Agenus.
NCT03673020 is a Phase 1 study that has completed, run by Agenus. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03673020, a Phase 1 study, has completed, sponsored by Agenus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.
Primary Outcome
Assessed by monitoring the frequency, duration, and severity of drug-related AEs by completing physical examinations and clinical evaluations; evaluating changes in vital signs; and laboratory blood and urine sample evaluations.
Interventions
- BIOLOGICAL ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2021-02-03 |
| Phase | Phase 1 |
What the finished NCT03673020 record still lists
NCT03673020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which ASV® AGEN2017 + QS-21 Stimulon® adjuvant is the first listed.
NCT03673020 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03673020 about?
NCT03673020 is a clinical study titled "Phase 1a Study to Evaluate Immunogenicity of ASV®". This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.
What is the current status of trial NCT03673020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-05-16. Estimated completion is 2021-02-03.
What interventions are being tested in trial NCT03673020?
The interventions under investigation include: ASV® AGEN2017 + QS-21 Stimulon® adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT03673020?
This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03673020's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI